Phase 3 Bladder Cancer Trial, Recruiting NCT04947059 Sponsor: University of Thessaly Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT04947059
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a bladder tumor, either newly diagnosed or one that has come back after previous treatment
  • Your surgery involves a standard type of bladder tumor removal procedure (using either bipolar or monopolar equipment)
  • Your kidney function blood test result is below a certain level (creatinine less than 2.2 mg/dl)
  • Your red blood cell level (hematocrit) falls within a healthy range (between 35% and 52%)
  • Your white blood cell count is at an acceptable level (at least 3,000 per microliter)
  • Your platelet count falls within an acceptable range (between 75,000 and 500,000 per microliter)
  • Your urine test shows no signs of infection
  • Your liver function blood test results are within an acceptable range (no more than twice the upper normal limit)
  • You are in good general health and able to carry out daily activities with little or no difficulty
  • A scan of your urinary tract done within the last 3 months showed no signs of tumor in the upper urinary tract (kidneys or ureters)

Who may not be able to join:

  • You have had more than 2 low-grade (slow-growing) bladder tumors confirmed by biopsy in the last 18 months before your surgery
  • You have had a high-grade (fast-growing) bladder tumor confirmed by biopsy in the last 9 months before your surgery
  • Your tumor removal surgery was incomplete, or the tissue sample did not contain the required muscle layer (with some specific exceptions — confirm with trial site)
  • You have received chemotherapy directly into the bladder or a treatment called BCG in the last 6 months before your surgery
  • You have a history of a type of bladder cancer that does not originate from the bladder lining (non-urothelial bladder cancer)
  • Your bladder cancer has grown into the bladder muscle (stage pT2 or muscle-invasive disease)
  • You have a tumor present in the urethra (the tube that carries urine out of the body)
  • You have had or currently have a cancer in the upper urinary tract (kidneys or ureters)
  • You have previously had radiotherapy (radiation treatment) to the pelvic area
  • You have been diagnosed with any other type of cancer within the last 5 years before your bladder surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vasileios Tzortzis, Professor, Urology Department, University of Thessaly, University Hospital of Larissa, Greece

Phone: 00302413502811

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Thessaly
Registry
ClinicalTrials.gov
Start date
14 December 2021
Est. completion
1 October 2025

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Bladder cancer recurrence; Bladder cancer progression; Bladder cancer recurrence; Bladder cancer progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov